FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4289839389> ?p ?o ?g. }

• W4289839389 endingPage "206" @default.
• W4289839389 startingPage "201" @default.
• W4289839389 abstract "Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by tumoral overproduction of FGF-23. Due to local recurrence, we describe the long-term efficacy and safety profile of burosumab, an anti-FGF-23 monoclonal antibody, in a TIO patient after three unsuccessfully surgical attempts. TIO is a rare paraneoplastic syndrome caused by tumoral overproduction of fibroblast growth factor 23 (FGF23), resulting in hyperphospaturia, hypophosphatemia, and osteomalacia. Surgery is the only definitive treatment, but tumor can locally recur, even after years from primary surgery. Furthermore, some tumors cannot be removed by surgery due to their location. We describe the case of a 54-year-old woman affected by recurrent TIO who, after three unsuccessful surgical attempts of tumor removal, was treated with burosumab, an anti-FGF-23 monoclonal antibody. The patient was referred to our Bone Unit after experiencing several fractures in different sites, both traumatic and non-traumatic. At the time of first evaluation, at the age of 46, serum-phosphate (SP) was 1.2 mg/dL (reference range (RR) 2.5–4.5), 24-h urinary phosphate was 842 mg (RR 400–1000), and intact-FGF-23 was 117 pg/mL (RR 25–45). Imaging showed a metabolic pre-sacral lesion that firstly underwent to exploratory laparotomy. Then, patient underwent to surgical excision of tumor. After 18 months of well-being, tumor relapsed and even the subsequent surgery was not able to completely remove it. Since 2015, patient was maintained in phosphorus supplements and 1,25(OH)2vitamin D3, but SP levels never normalized. In September 2019, she was started on burosumab, initially at the dose of 0.3 mg/kg/month, progressively increased to the current 0.8 mg/kg/month, with great improvement of pain, physical performance, and normalization of SP levels. Burosumab was temporary and cautionary discontinued for COVID-19 pneumonia, with a worsening of SP. After restart of burosumab, biochemistry returned to normal. To our knowledge, this is the first European patient affected by TIO treated with burosumab for more than 2 years. Burosumab is a promising therapy in the medical treatment of TIO refractory or not eligible for definitive surgery, with good efficacy and safety profile." @default.
• W4289839389 created "2022-08-05" @default.
• W4289839389 creator A5000845595 @default.
• W4289839389 creator A5021483355 @default.
• W4289839389 creator A5033475281 @default.
• W4289839389 creator A5049341852 @default.
• W4289839389 creator A5053288231 @default.
• W4289839389 date "2022-08-04" @default.
• W4289839389 modified "2023-10-11" @default.
• W4289839389 title "Long-term use of burosumab for the treatment of tumor-induced osteomalacia" @default.
• W4289839389 cites W1877345851 @default.
• W4289839389 cites W1965642438 @default.
• W4289839389 cites W2001067211 @default.
• W4289839389 cites W2017452957 @default.
• W4289839389 cites W2019081168 @default.
• W4289839389 cites W2020598094 @default.
• W4289839389 cites W2507785154 @default.
• W4289839389 cites W2600981785 @default.
• W4289839389 cites W2736265510 @default.
• W4289839389 cites W2800395726 @default.
• W4289839389 cites W2803769911 @default.
• W4289839389 cites W2964766363 @default.
• W4289839389 cites W3032944526 @default.
• W4289839389 cites W3043630716 @default.
• W4289839389 cites W3083897501 @default.
• W4289839389 cites W3087963210 @default.
• W4289839389 cites W3114617368 @default.
• W4289839389 cites W3152237930 @default.
• W4289839389 cites W3176180235 @default.
• W4289839389 cites W4225943562 @default.
• W4289839389 cites W4281740062 @default.
• W4289839389 doi "https://doi.org/10.1007/s00198-022-06516-6" @default.
• W4289839389 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35925260" @default.
• W4289839389 hasPublicationYear "2022" @default.
• W4289839389 type Work @default.
• W4289839389 citedByCount "7" @default.
• W4289839389 countsByYear W42898393892022 @default.
• W4289839389 countsByYear W42898393892023 @default.
• W4289839389 crossrefType "journal-article" @default.
• W4289839389 hasAuthorship W4289839389A5000845595 @default.
• W4289839389 hasAuthorship W4289839389A5021483355 @default.
• W4289839389 hasAuthorship W4289839389A5033475281 @default.
• W4289839389 hasAuthorship W4289839389A5049341852 @default.
• W4289839389 hasAuthorship W4289839389A5053288231 @default.
• W4289839389 hasBestOaLocation W42898393891 @default.
• W4289839389 hasConcept C114276007 @default.
• W4289839389 hasConcept C124490489 @default.
• W4289839389 hasConcept C126322002 @default.
• W4289839389 hasConcept C141071460 @default.
• W4289839389 hasConcept C142724271 @default.
• W4289839389 hasConcept C2778049618 @default.
• W4289839389 hasConcept C2778573388 @default.
• W4289839389 hasConcept C2781156865 @default.
• W4289839389 hasConcept C2781208988 @default.
• W4289839389 hasConcept C519063684 @default.
• W4289839389 hasConcept C71924100 @default.
• W4289839389 hasConcept C90924648 @default.
• W4289839389 hasConceptScore W4289839389C114276007 @default.
• W4289839389 hasConceptScore W4289839389C124490489 @default.
• W4289839389 hasConceptScore W4289839389C126322002 @default.
• W4289839389 hasConceptScore W4289839389C141071460 @default.
• W4289839389 hasConceptScore W4289839389C142724271 @default.
• W4289839389 hasConceptScore W4289839389C2778049618 @default.
• W4289839389 hasConceptScore W4289839389C2778573388 @default.
• W4289839389 hasConceptScore W4289839389C2781156865 @default.
• W4289839389 hasConceptScore W4289839389C2781208988 @default.
• W4289839389 hasConceptScore W4289839389C519063684 @default.
• W4289839389 hasConceptScore W4289839389C71924100 @default.
• W4289839389 hasConceptScore W4289839389C90924648 @default.
• W4289839389 hasIssue "1" @default.
• W4289839389 hasLocation W42898393891 @default.
• W4289839389 hasLocation W42898393892 @default.
• W4289839389 hasLocation W42898393893 @default.
• W4289839389 hasOpenAccess W4289839389 @default.
• W4289839389 hasPrimaryLocation W42898393891 @default.
• W4289839389 hasRelatedWork W1564099730 @default.
• W4289839389 hasRelatedWork W2033342055 @default.
• W4289839389 hasRelatedWork W2033791768 @default.
• W4289839389 hasRelatedWork W2118662201 @default.
• W4289839389 hasRelatedWork W2164952534 @default.
• W4289839389 hasRelatedWork W2415895083 @default.
• W4289839389 hasRelatedWork W2618710159 @default.
• W4289839389 hasRelatedWork W3167885582 @default.
• W4289839389 hasRelatedWork W3213909817 @default.
• W4289839389 hasRelatedWork W4306385470 @default.
• W4289839389 hasVolume "34" @default.
• W4289839389 isParatext "false" @default.
• W4289839389 isRetracted "false" @default.
• W4289839389 workType "article" @default.